News
As ECCO 2025 unfolds, all eyes will be on how these new data sets will further shape the evolving IBD treatment paradigm. Gaja Gasiorek is a senior business analyst at Lifescience Dynamics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback